Edition:
United States

Sarepta Therapeutics Inc (SRPT.O)

SRPT.O on Nasdaq

60.98USD
29 Sep 2016
Change (% chg)

-- (--)
Prev Close
$60.98
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,797,823
52-wk High
$63.73
52-wk Low
$8.00

Select another date:

Thu, Sep 22 2016

BRIEF-Sarepta Therapeutics reports pricing of $300 million public offering of common stock

* Sarepta Therapeutics announces pricing of $300 million public offering of common stock

BRIEF-Sarepta Therapeutics announces offering to sell up to $225 mln of stock

* Sarepta Therapeutics announces proposed public offering of common stock

Bowing to pressure, FDA approves Sarepta's Duchenne drug

Bowing to pressure from patient advocates, the U.S. Food and Drug Administration on Monday approved a treatment for Duchenne muscular dystrophy even though an outside panel of experts and the agency's own reviewers questioned the drug's efficacy.

UPDATE 3-Bowing to pressure, U.S. FDA approves Sarepta's Duchenne drug

Sept 19 Bowing to pressure from patient advocates, the U.S. Food and Drug Administration on Monday approved a treatment for Duchenne muscular dystrophy even though an outside panel of experts and the agency's own reviewers questioned the drug's efficacy.

BRIEF-Sarepta Therapeutics says U.S. Commercial launch for Exondys 51 planned to commence immediately

* Sarepta therapeutics announces fda accelerated approval of exondys 51(tm) (eteplirsen) injection, an exon skipping therapy to treat duchenne muscular dystrophy (dmd) patients amenable to skipping exon 51

Sarepta's keenly watched muscle dystrophy drug wins FDA approval

Sept 19 Sarepta Therapeutics Inc's Duchenne muscular dystrophy drug won approval from the U.S. Food and Drug Administration on Monday, capping months of regulatory uncertainty and pressure from parents and patient advocates to endorse it.

Sarepta jumps on drug approval hopes after FDA critic departs

Shares of Sarepta Therapeutics Inc rose as much as 29 percent after a key critic of its muscle-wasting drug left the U.S. Food and Drug Administration ahead of the agency's decision whether to approve it.

UPDATE 1-Sarepta jumps on drug approval hopes after FDA critic departs

Sept 14 Shares of Sarepta Therapeutics Inc rose as much as 29 percent after a key critic of its muscle-wasting drug left the U.S. Food and Drug Administration ahead of the agency's decision whether to approve it.

Sarepta jumps on drug approval hopes after FDA critic departs

Sept 14 Shares of Sarepta Therapeutics Inc rose as much as 29 percent after a key critic of its muscle-wasting drug left the U.S. Food and Drug Administration ahead of the agency's decision whether to approve it.

BRIEF-Sarepta Therapeutics Q2 non-GAAP loss per share $1.19 excluding items

* No revenue was recognized for three months ended June 30, 2016 and 2015

Select another date: